TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04659122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-100
Description: reconstituted AT-100 for intratracheal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-100
Description: reconstituted AT-100 for intratracheal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-100
Description: reconstituted AT-100 for intratracheal administration
Study: NCT05167890

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee
Description: Coffee 3 times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: Orange juice 3 times per day
Study: NCT04703998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: A double-row rotator cuff repair will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Description: A double-row rotator cuff repair will be performed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
Study: NCT05173337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.~20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery.
Study: NCT04683003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-755
Description: TAK-755 IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-755
Description: TAK-755 IV infusion
Study: NCT04835792

Intervention type: OTHER
Intervention: Stool and blood collection
Description: One-time stool and blood collection

Intervention type: OTHER
Intervention: Stool and blood collection
Description: One-time stool and blood collection
Study: NCT04693039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Study: NCT05555576

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
Study: NCT05103800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invasive interventions
Description: listening the white noise during the invasive interventions
Study: NCT06235320

Intervention type: OTHER
Intervention: routine clinical treatment of pain with paracetamol or ibuprofen
Description: No intervention beside clinical routine management

Intervention type: OTHER
Intervention: routine clinical treatment of pain with paracetamol or ibuprofen
Description: No intervention beside clinical routine management
Study: NCT04687189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)
Description: Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)
Description: Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
Study: NCT05184387

Intervention type: OTHER
Intervention: Blood samples
Description: Collection of blood samples and completion of an electronic Diary (eDiary)
Study: NCT05444270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard salvage therapy
Description: Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard salvage therapy + SABR
Description: Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
Study: NCT04997772

Intervention type: DEVICE
Intervention: Digital Gaucher Platform
Description: Digital platform specified for Gaucher patients.
Study: NCT06463782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-LNC1007 Injection
Description: The participant will receive a single intravenous injection with 0.05 mCi/kg (according to the participants' body weight) 68Ga-LNC1007 Injection on the scan bed. The final dose of the drug is allowed to fluctuate within the 20% range, but not below 3 mCi. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
Study: NCT05241353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Frequency Self-Monitoring
Description: Participants will be asked to record only a subset of daily eating throughout the intervention, with the prescription for self-monitoring individually tailored at baseline dependent on participants' self-reported eating patterns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full-Frequency Self-Monitoring
Description: Participants will be asked to record all contents of their diet throughout the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Treatment
Description: Participants will receive four individual coaching calls over 12 weeks. During coaching calls, participants will receive guidance on lowering calorie intake, increasing physical activity and use of specific behavioral strategies to increase the probability of success with weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment
Description: Participants will receive four individual coaching calls over 12 weeks. During coaching calls, participants will receive guidance on lowering calorie intake, increasing physical activity and use of specific behavioral strategies to increase the probability of success with weight loss.
Study: NCT06266208

Intervention type: PROCEDURE
Intervention: Exostectomy
Description: Patients diagnosed with dorsal osteophyte and experiencing pain were advised to proceed with osteophyte removal surgery during their initial visit.The surgical procedure, following protocol occurred during the second visit and involved the following steps: a 2-4 mm incision using a Beaver-64-MIS scalpel on the distal surface wall of the toe, parallel to its longitudinal axis, followed by careful osteophyte drilling; precise delineation of the osteophyte contour using a blunt elevator to prevent nailbed damage; resection executed through medial and lateral movements facilitated by a mini-Shannon drill; and finally, pressure application with a surgical spoon to extract the bone paste resulting from the drilling process.

Intervention type: PROCEDURE
Intervention: Cut fingernail
Description: Patients diagnosed with dorsal osteophyte and experiencing pain underwent nail cut fingernail
Study: NCT05667181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surform
Description: Da Vinci linear cutting stapler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surform
Description: Da Vinci linear cutting stapler
Study: NCT04956705

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium
Description: Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
Study: NCT05774288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cera™ patent foramen ovale occluders
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Another patent foramen ovale occluders
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
Study: NCT06155708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: - Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
Study: NCT04892017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral Tablet Formulation
Study: NCT06081218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity test
Description: Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: activity test
Description: Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
Study: NCT05102864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex
Description: iTBS will be administered to the left DLPFC for 10 consecutive days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex
Description: iTBS will be administered to the left DLPFC for 10 consecutive days
Study: NCT05030948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiempo Juntos Intervention
Description: If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging.
Study: NCT06429605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: In addition to our standard clinical protocol, study patients were administered 60 mg oral duloxetine 2 hours before surgery and 24 hours after surgery
Study: NCT06360289

Intervention type: OTHER
Intervention: Standard of Care
Description: This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.

Intervention type: OTHER
Intervention: Standard of Care
Description: This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.
Study: NCT06422923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NRTX-1001
Description: Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.
Study: NCT05443594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase 1: FARAPULSE Ablation System
Description: PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase 2: FARAPULSE Ablation System
Description: PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.
Study: NCT05935358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq
Description: Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
Study: NCT06775327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000631
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet
Study: NCT06777108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inorganic Nitrate
Description: The intervention evaluates the single and 1/2-dose pharmacokinetics of a plant-based bioequivalent inorganic nitrate (NO3-) complex with vitamins, antioxidantsand phytophenol rich food extracts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inorganic Nitrate
Description: The intervention evaluates the single and 1/2-dose pharmacokinetics of a plant-based bioequivalent inorganic nitrate (NO3-) complex with vitamins, antioxidantsand phytophenol rich food extracts.
Study: NCT06469151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5148
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5148
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5148
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5148
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5148
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5148
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5148
Description: Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus
Study: NCT05588479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Two capsules of pomegranate extract (740 mg) will be taken daily at any time of the day for a period of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
Study: NCT05236192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Root Home Visitation (TRHV)
Description: TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual (SAU)
Description: SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
Study: NCT06296173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective open-lung extubation
Description: Emergence using 50% FiO2, semi-sitting position with pressure support ventilation and preserved PEEP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional extubation
Description: Emergence using 100% FiO2, dorsal decubitus position with assistance or manual bag ventilation without PEEP
Study: NCT04163614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IBPS-Guided Ultrafiltration
Description: Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
Study: NCT05051436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Mirabegron 50 mg/day will be administered for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Mirabegron 50 mg/day will be administered for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered for 14 weeks after baseline procedures.
Study: NCT05331521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CETEG
Description: At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCV
Description: In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RT
Description: Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade 2 and 59.4 Gy in 1.8 Gy fractions for grade 3 gliomas
Study: NCT06439056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEX-22A, a prolonged release formulation of liraglutide
Description: NEX-22A, a prolonged release formulation of liraglutide